Back

Penitrium study cuts ovarian cancer organoid viability to 12.8%

Verifying
  • Penitrium Bioscience presented organoid research evaluating Penitrium with daraxonrasib.
  • 12.8% was the ovarian cancer organoid viability after combination treatment.
  • FDA approved the U.S. investigational drug application this month; the trial targets September 2028 completion.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Penitrium study cuts ovarian cancer organoid viability to 12.8% - CoinPost Terminal